Guillain-Barré Syndrome Incidence Declined 9% in Japan During the Pandemic

Shifting Phenotypes of Acute Polyneuropathy in the Pandemic Era

The relationship between viral outbreaks and the incidence of Guillain-Barré syndrome remains a critical focus for clinicians, as infections are well-recognized triggers for neuroinflammatory cascades [1, 2]. Since the emergence of SARS-CoV-2, systematic reviews of up to 436 patients have documented a diverse spectrum of peripheral nervous system complications, ranging from classic sensorimotor forms to rare variants like Miller Fisher syndrome (a clinical triad of ataxia, areflexia, and ophthalmoplegia) [3, 4, 5]. While early data suggested a potential increase in cases with a median onset of 10 to 19 days post-infection, large-scale epidemiological studies found no clear causative link, with one UK analysis reporting a non-significant correlation between the two conditions (r = 0.06, 95% CI: -0.56 to 0.63) [3, 6, 7]. In fact, nationwide data from Japan using an interrupted time series (a statistical method used to evaluate the impact of a specific event or intervention by comparing trends before and after the event) demonstrated that Guillain-Barré syndrome incidence significantly declined (P < 0.001) during the pandemic [1]. This reduction likely reflects the impact of non-pharmaceutical interventions, such as social distancing and enhanced hygiene, which limited exposure to conventional triggers like Campylobacter jejuni and common respiratory viruses [7, 1, 8]. A comprehensive nationwide analysis now provides a clearer picture of how these competing factors reshaped the clinical landscape of acute inflammatory polyneuropathy.

Quantifying the Reduction in National Incidence

To evaluate the epidemiological shifts in acute inflammatory polyneuropathy, researchers conducted a nationwide survey on the incidence of Guillain-Barré syndrome in Japan between 2017 and 2022. This comprehensive study period was designed to capture data across two distinct intervals: the pre-pandemic period, spanning 2017 to 2019, and the pandemic period, covering 2020 to 2022. The researchers utilized a two-stage data collection process, sending questionnaires to neurology and pediatrics departments at hospitals throughout the country. A primary questionnaire was deployed to estimate the total number of patients and the overall incidence, while a second questionnaire was administered to collect detailed clinical information on the affected individuals. This methodology allowed for a robust comparison of how the syndrome's frequency changed as public health behaviors shifted on a national scale.

The data revealed a clear downward trend in the frequency of the condition during the earlier phase of the COVID-19 pandemic. During the pre-pandemic period, the estimated annual number of newly diagnosed Guillain-Barré syndrome cases was 1,885 (95% CI, 1,766 to 2,004), which corresponded to an incidence of 1.49 per 100,000 population (95% CI, 1.40 to 1.58). In contrast, during the pandemic period, the estimated annual number of newly diagnosed cases fell to 1,603 (95% CI, 1,463 to 1,743), resulting in a lower incidence of 1.28 per 100,000 population (95% CI, 1.17 to 1.39). Statistical analysis confirmed that the relative risk for Guillain-Barré syndrome incidence during the pandemic period was 0.91 (95% CI, 0.83 to 0.99), representing a 9% reduction in the risk of developing the syndrome compared to the years immediately preceding the global health crisis. For the practicing clinician, these findings suggest that the overall burden of acute polyneuropathy decreased as the transmission of traditional infectious triggers was suppressed.

Altered Clinical Profiles and Diagnostic Subtypes

The researchers analyzed detailed clinical profiles for 2,623 patients, comprising 1,420 individuals from the pre-pandemic period and 1,203 from the pandemic period, to identify shifts in the presentation of the syndrome. Patients diagnosed during the pandemic were significantly older, with a median age of 56 years compared to 53 years in the pre-pandemic cohort (P = 0.02). This demographic shift coincided with a notable change in the suspected triggers of the disease. Specifically, a higher proportion of pandemic-era cases occurred without any antecedent infectious episodes, rising to 38.2% from 24.5% in the preceding years (P < 0.0001). This suggests that the public health measures implemented to curb the spread of respiratory and gastrointestinal pathogens may have altered the typical immunological landscape of the condition, potentially leaving clinicians to manage more cases where the inciting event remains occult.

Clinical progression also showed distinct variations during the pandemic years. The time to reach the nadir, defined as the point of maximum clinical weakness before stabilization begins, was significantly longer during the pandemic period, with a median of 8 days compared to 7 days in the pre-pandemic group (P = 0.0418). Furthermore, the researchers observed a shift in the underlying pathology of the cases. The frequency of the demyelinating subtype of Guillain-Barré syndrome was higher during the pandemic, accounting for 37.8% of cases compared to 32.6% previously (P = 0.0068). This subtype involves an immune-mediated attack on the myelin sheath, the fatty insulation of the nerve, rather than the axon itself. Despite these changes in age, onset triggers, and diagnostic subtypes, the long-term prognosis for patients remained stable. No significant differences were observed in clinical outcomes at 6 months post-onset between the pre-pandemic and pandemic groups, indicating that while the initial presentation and subtype distribution shifted, the overall recovery trajectory for patients in Japan did not worsen during the global health crisis.

The Role of Diminished Enteric Triggers

The observed epidemiological shift in Guillain-Barré syndrome appears closely linked to changes in the prevalence of common gastrointestinal pathogens during the pandemic. According to Japanese national registry data, there was a markedly reduced number of Campylobacter-related enteritis cases following the implementation of widespread public health measures and social distancing. This reduction in enteric infections is clinically significant because Campylobacter jejuni is a well-established trigger for the axonal forms of the syndrome through molecular mimicry, a process where the immune system confuses microbial antigens with similar-looking components of the peripheral nerves. The researchers suggest that the increased proportion of cases without preceding infectious episodes or those presenting with demyelinating subtypes may be caused by reduced exposure to these conventional triggers, such as Campylobacter jejuni, which typically drive a different immunological profile.

Beyond the decline of traditional pathogens, the authors hypothesize that the changing clinical landscape may be influenced by the pandemic virus itself. They suggest that increased asymptomatic COVID-19-related demyelinating Guillain-Barré syndrome may have contributed to the observed clinical shifts, specifically the rise in the demyelinating subtype to 37.8 percent of cases. This hypothesis implies that while symptomatic respiratory infections were being monitored, subclinical SARS-CoV-2 infections might have been acting as a primary driver for the demyelinating phenotype (a form of the disease where the immune system attacks the protective myelin sheath of the nerves rather than the axons themselves). This shift in triggers explains why the incidence of the syndrome fell overall while the relative frequency of specific clinical presentations and older patient demographics increased. For the neurologist, these data underscore the importance of considering a broad range of potential triggers, including subclinical viral exposure, when evaluating acute polyneuropathy in the post-pandemic era.

References

1. Akada M, Hata M, Miyake M, et al. Natural experiment on neuroinflammatory disease incidence and infection links pre- and post-COVID-19. Brain. 2025. doi:10.1093/brain/awaf458

2. Saad MA, Alfishawy M, Nassar M, Mohamed M, Esene IN, Elbendary A. COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases.. Current rheumatology reviews. 2021. doi:10.2174/1573397116666201029155856

3. Pimentel V, Luchsinger VW, Carvalho GL, et al. Guillain–Barré syndrome associated with COVID-19: A systematic review. Brain Behavior & Immunity - Health. 2023. doi:10.1016/j.bbih.2022.100578

4. Abu‐Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology. 2020. doi:10.1007/s00415-020-10124-x

5. Orrù G, Conversano C, Malloggi E, Francesconi F, Ciacchini R, Gemignani A. Neurological Complications of COVID-19 and Possible Neuroinvasion Pathways: A Systematic Review. International Journal of Environmental Research and Public Health. 2020. doi:10.3390/ijerph17186688

6. Sanctis PD, Doneddu PE, Viganó LLS, Selmi C, Nobile‐Orazio E. Guillain–Barré syndrome associated with SARS‐CoV‐2 infection. A systematic review. European Journal of Neurology. 2020. doi:10.1111/ene.14462

7. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2020. doi:10.1093/brain/awaa433

8. Leung MTY, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerging Microbes & Infections. 2020. doi:10.1080/22221751.2020.1825914